Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study)

Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study)

Bibliographic Details
Main Authors: J. Van Wyk, F. Ajana, F. Bisshop, S. De Wit, Y. Osiyemi, J. Portilla, J. Routy, C. Wyen, M. Ait-Khaled, M. Nascimento, K. Pappa, R. Wang, J. Wright, A. Tenorio, B. Wynne, M. Aboud, M. Gartland, K. Smith, Y. El-Bahy
Format: Article
Language:English
Published: Elsevier 2020-02-01
Series:Journal of Infection and Public Health
Online Access:http://www.sciencedirect.com/science/article/pii/S1876034120301180

Internet

http://www.sciencedirect.com/science/article/pii/S1876034120301180

Similar Items